Below is an email I sent today to Nader Pourhassan:
Dr. Pourhassan:
I have previously written to you with suggestions as to how any future interviews can better present the success, to date, of Leronlimab.
To reiterate, I would respectfully offer the following:
As politicians do, any person being interviewed needs to script what he/she wants to say, and pivot from the question asked, and give such scripted answers.
In the four minutes you were interviewed by Charles Payne, for example, you could have been prepared to say, and pivoted to make the following points (which should, of course, be edited by you for accuracy):
1. 4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
2. The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
3. The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
4. In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
5. Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
If you make these comments, in response to whatever questions Charles Payne or any interviewer hereafter offers, the viewers would likely come away with a very favorable impression of Leronlimab.
In any future pre-interview with Payne, or any other interviewer, you might want to advise him/her of the above, so he/she would be able to ask questions that would be conducive to eliciting this information.
However, if the questions by Payne, or any future interviewer, are not phrased so as to elicit this information, I would respectfully suggest that you pivot, and provide this information, just as every politician pivots in responding to questions from reporters.
Thank you,
[Name Deleted]
Cytodyn Shareholder
Dr. Pourhassan:
I have previously written to you with suggestions as to how any future interviews can better present the success, to date, of Leronlimab.
To reiterate, I would respectfully offer the following:
As politicians do, any person being interviewed needs to script what he/she wants to say, and pivot from the question asked, and give such scripted answers.
In the four minutes you were interviewed by Charles Payne, for example, you could have been prepared to say, and pivoted to make the following points (which should, of course, be edited by you for accuracy):
1. 4 out of 9 seriously ill Covid-19 patients who were treated with Leronlimab at a leading New York City hospital, were able to be taken off of their ventilators after only three days.
2. The immune function in all 9 of these seriously ill Covid-19 patients was fully restored after 7 days, while their cytokine storms were reduced between 70 and 90 percent.
3. The patients who improved greatly on Leronlimab had previously been treated, without success, on either hydroxychloride or remdesivir.
In other words, these 9 patients had better results after being treated with Leronlimab than they had after being treated with either hydroxychloride or remdesivir.
4. In over 800 patients who have been treated with Leronlimab for HIV and metastatic breast cancer over the past five years, there has not been one serious adverse event attributable to this drug.
In other words, other than some pain at the injection site--and the injection is only subcutaneous, the same as an insulin injection--there are virtually no side effects from Leronlimab.
5. Leronlimab is now in two FDA approved clinical trials for mild to moderate, and seriously ill, Covid-19 patients.
Cytodyn expects to have at least some results from these trials within 30 days.
If you make these comments, in response to whatever questions Charles Payne or any interviewer hereafter offers, the viewers would likely come away with a very favorable impression of Leronlimab.
In any future pre-interview with Payne, or any other interviewer, you might want to advise him/her of the above, so he/she would be able to ask questions that would be conducive to eliciting this information.
However, if the questions by Payne, or any future interviewer, are not phrased so as to elicit this information, I would respectfully suggest that you pivot, and provide this information, just as every politician pivots in responding to questions from reporters.
Thank you,
[Name Deleted]
Cytodyn Shareholder
2
CytoDyn Inc (CYDY) Stock Research Links
The Lawman[img]
